GlaxoSmithKline PLC (NYSE:GSK) – Analysts at Leerink Swann lowered their Q3 2017 earnings estimates for GlaxoSmithKline PLC in a research report issued to clients and investors on Wednesday. Leerink Swann analyst S. Fernandez now expects that the pharmaceutical company will earn $0.81 per share for the quarter, down from their previous forecast of $0.85. Leerink Swann also issued estimates for GlaxoSmithKline PLC’s Q4 2017 earnings at $0.75 EPS and FY2021 earnings at $3.22 EPS.

GlaxoSmithKline PLC (NYSE:GSK) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. The firm had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%.

TRADEMARK VIOLATION NOTICE: “Leerink Swann Analysts Cut Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/28/leerink-swann-analysts-cut-earnings-estimates-for-glaxosmithkline-plc-nysegsk.html.

A number of other analysts have also weighed in on GSK. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, April 5th. BNP Paribas raised shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and lowered their price target for the company from $45.58 to $37.20 in a report on Wednesday, April 5th. Exane BNP Paribas raised shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating in a report on Wednesday, April 5th. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a report on Monday, April 17th. Finally, TheStreet raised shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. GlaxoSmithKline PLC presently has a consensus rating of “Hold” and an average target price of $46.00.

Shares of GlaxoSmithKline PLC (GSK) opened at 40.75 on Friday. The firm has a market capitalization of $99.55 billion, a P/E ratio of 45.58 and a beta of 1.04. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $45.58. The firm has a 50-day moving average price of $42.93 and a 200-day moving average price of $41.77.

Several institutional investors have recently made changes to their positions in the company. Lincluden Management Ltd. boosted its position in shares of GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares in the last quarter. 10 15 Associates Inc. boosted its position in shares of GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares in the last quarter. Anchor Capital Advisors LLC boosted its position in shares of GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares in the last quarter. Roundview Capital LLC boosted its position in shares of GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock worth $1,034,000 after buying an additional 15,000 shares in the last quarter. Finally, Wesbanco Bank Inc. boosted its position in shares of GlaxoSmithKline PLC by 2.8% in the first quarter. Wesbanco Bank Inc. now owns 12,765 shares of the pharmaceutical company’s stock worth $538,000 after buying an additional 350 shares in the last quarter. 8.98% of the stock is currently owned by institutional investors.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be given a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.82%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 194.00%.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.